Oasmia completes its management team
Oasmia has further strengthen its management team with the recruitment of two General Managers to accelerate commercialization of Oasmia. Neil Yman is appointed General Manager for Europe & Russia and Reinhard Koenig is appointed General Manager for USA & Canada. Both have extensive experience of leading positions within global pharmaceutical companies.
“The addition of two experienced General Managers will drive the commercial success in their territory respectively. Oasmia has now a management team with the experience and standing to make a difference in this exciting transition period going forward. In addition, Oasmia continues adding more key employees with strong commercial as well as oncology experience in order to prepare for the launch and market access of Apealea - our first drug to the market“, comments Sven Rohmann CEO of Oasmia.
"This is a very important step-up for Oasmia. In my view, Oasmia has now a great team of employees. This is more than half of the success factor when we look ahead", says Jörgen Olsson, Chairman of the Board in Oasmia.
Moreover, Oasmia has recruited Carina Eklöw as Global Medical Affairs Director and Nigel Goodman as Clinical Operations Director.
The Oasmia management team is now complete and consists of:
CEO (interim), Sven Rohmann - ex Novartis, Ganymed Pharmaceuticals, Merck-Serono. 32 years of pharma and oncology experience.
CBO and Deputy CEO, Anette Sjödin - ex Nestlé Skin Health, Pharmacia, Biacore. 30 years of biotechnology and life science experience.
CTO, Mikael Asp - 30 years of experience from several companies within the international pharmaceutical industry in R&D, production, quality assurance and as Qualified Person (QP).
CMO, Nina Heldring – more than 20 years of experience with pre-clinical and clinical medical research from renowned academic institutes and the pharmaceutical industry.
GM USA & Canada, Reinhard Koenig - ex Genentech, Boehringer Mannheim, Piramal Critical Care. More than 30 years of pharma and biotechnology experience.
CFO (acting), Joakim Lindén - more than 25 years of experience of change implementation in public and private limited companies in many industries, countries and roles, including as CFO.
GM Europe & Russia, Neil Yman - ex Pierre Fabre, Novartis, GSK and Roche. Over 17 years of pharma and oncology experience.
For more information:
Investor Relations Oasmia
E-mail: IR@oasmia.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
Attachment
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer27.1.2020 07:00:00 CET | Press release
·Application is being reviewed under FDA’s Real-Time Oncology Review pilot programme Basel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. In July 2018, the FDA granted Breakthrough Therapy Designation for Tecentriq in combination with Avastin in HCC based on data from an ongoing Phase Ib trial. “Liver cancer is the most rapidly increasing cause of cancer-related death in the United States. In the IMbrave150 study, Tece
Media Release | MCH Group | Extraordinary General Meeting - Shareholder Questions27.1.2020 07:00:00 CET | Press release
Extraordinary General Meeting of MCH Group Ltd. on 29 January 2020: Board of Directors answers shareholder’s questions With the view to the Extraordinary General Meeting on 29 January 2020, MCH Group Ltd. has published the written answers to the list of questions submitted by a shareholder group. As one of various options for financing the investments required as part of the strategic realignment, the Board of Directors is examining the participation of new investors at group level, which can be combined with a capital increase and structural changes. On 26 November 2019, AMG Fondsverwaltung AG, representing the AMG Group (comprising Ursula Lee, Erhard Lee and LLB Swiss Investment AG and acting on behalf of AMG Substanzwerte Schweiz), requested the convocation of an Extraordinary General Meeting and submitted motions for the initiation of a special review of the strategy, for the disclosure of business records and for changes to the Statutes. In conjunction with the motion for the init
Beslut vid årsstämman i Eolus Vind AB den 25 januari 202025.1.2020 17:45:00 CET | Pressemelding
Hässleholm den 25 januari 2020. I enlighet med styrelsens förslag fastställde årsstämman utdelningen för räkenskapsåret 2018/2019 till 1,50 kronor per aktie med tisdagen den 28 januari 2020 som avstämningsdag. Bolagets styrelseledamöter och VD beviljades ansvarsfrihet. Sigrun Hjelmqvist, Hans Johansson, Jan Johansson, Hans Linnarson, Bodil Rosvall Jönsson samt Hans-Göran Stennert omvaldes till styrelseledamöter och Hans-Göran Stennert omvaldes som styrelsens ordförande. Registrerade revisionsbolaget PricewaterhouseCoopers AB omvaldes till revisor med auktoriserade revisorn Eva Carlsvi som huvudansvarig revisor. Arvode till styrelsen beslutades utgå med totalt 1 250 000 kronor, varav 375 000 kronor till ordföranden och 175 000 kronor vardera till övriga styrelseledamöter som inte är anställda i bolaget. Vidare beslutade stämman att arvode till revisorn ska utgå enligt avtal. I enlighet med förslag från valberedningen fastställde stämman instruktioner för utseende av valberedningen och v
Resolutions at the Annual General Meeting in Eolus Vind AB on January 25th, 202025.1.2020 17:45:00 CET | Press release
Hässleholm, Sweden, January 25th, 2020. In accordance with the Board of Directors’ proposal, the Annual General Meeting (“AGM”) resolved to declare a dividend of SEK 1.50 per share for the financial year 2018/2019, and the record date for the payment of dividends was set to Tuesday, January 28th, 2020. The Board members and the CEO were discharged from liability. Sigrun Hjelmqvist, Hans Johansson, Jan Johansson, Hans Linnarson, Bodil Rosvall Jönsson and Hans-Göran Stennert were re-elected as members of the Board of Directors and Hans-Göran Stennert was re-elected as chairman of the Board. Accounting firm PricewaterhouseCoopers AB was re-elected as the company’s auditor, with authorized public accountant Eva Carlsvi as auditor in charge. It was decided that fees to the Board of Directors shall amount to SEK 1,250,000 in total, whereby the fee to the chairman shall amount to SEK 375,000 and the fees for each of the other Board members that are not employed by the company shall amount to
Gold Lion Closes Acquisition of Cuteye Group of Properties24.1.2020 22:05:00 CET | Press release
VANCOUVER, British Columbia, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Gold Lion Resources Inc. (“Gold Lion” or the “Company”) (CSE: GL) (FWB: 2BC) is pleased to announce that it has closed its acquisition of the Cuteye Group of Properties from a private British Columbia numbered company (“Numberco”) (see the Company’s January 13, 2020 news release previously announcing the transaction). Under the transaction, Gold Lion issued an aggregate of 6,000,000 Gold Lion common shares to the shareholders of Numberco. No finder’s fees were paid in connection with the transaction. Gold Lion also announces the appointment of Mr. Dan Dente as a Director of the Company. Mr. Dente brings over 20 years’ experience within the financial services industry. About Gold Lion Resources Inc. Gold Lion Resources Inc. is a mineral exploration company, actively involved in the exploration of the Cuteye Group of Properties, as well as the Fairview Copper-Silver-Zinc Property. The Cuteye Group of Properties includes the M
Notice of fourth quarter 2019 results and conference call24.1.2020 18:05:00 CET | Press release
Notice of fourth quarter 2019 results and conference call Luxembourg, January 24th, 2020 – Millicom will announce its fourth quarter results for the period ending December 31st, 2019, on February 25th, 2020 at approximately 12:00 (Stockholm) / 11:00 (London) / 6:00 (Miami) via a press release. The company will host a conference call for the global financial community on February 25th, 2020 at 14:00 (Stockholm) / 13:00 (London) / 08:00 (Miami). The conference call will be webcast at www.millicom.com Dial-in information: Please dial in 5-10 minutes before the scheduled start time to register your attendance. Dial-in numbers for the call are as follows: Sweden: +46 (0) 8506 92180 Luxembourg: +352 2786 0515 UK: +44 (0) 2071 928000 US: +1 631 5107 495 The access code is: 2348098 Replay information: A replay of the call will be available for 7 days from February 25th, 2020 at: UK: +44 (0) 3333 009785 US: +1 (917) 677-7532 Replay passcode is: 2348098 For further information, please contact Pr